martes, 9 de diciembre de 2014

AHA: IMPROVE-IT Proves Ezetimibe Benefit

Published: Nov 17, 2014 | Updated: Nov 18, 2014

CHICAGO -- In high-risk patients, adding ezetimibe to statin therapy reduced LDL cholesterol by an average of 17 mg/dL and reduced cardiovascular events compared with statin therapy alone.
That finding from the 18,000-patient IMPROVE-IT trial marks the first time that adding a nonstatin lipid-lowering therapy to a statin demonstrated a clinical benefit, Christopher Cannon, MD, of Brigham and Women's Hospital, toldMedPage Today.

Completo aquí:

No hay comentarios:

Publicar un comentario